jm1c00679_si_003.csv (11.57 kB)
Download file

Discovery of IACS-9779 and IACS-70465 as Potent Inhibitors Targeting Indoleamine 2,3-Dioxygenase 1 (IDO1) Apoenzyme

Download (11.57 kB)
dataset
posted on 22.07.2021, 17:11 authored by Matthew M. Hamilton, Faika Mseeh, Timothy J. McAfoos, Paul G. Leonard, Naphtali J. Reyna, Angela L. Harris, Alan Xu, Michelle Han, Michael J. Soth, Barbara Czako, Jay P. Theroff, Pijus K. Mandal, Jason P. Burke, Brett Virgin-Downey, Alessia Petrocchi, Dana Pfaffinger, Norma E. Rogers, Connor A. Parker, Simon S. Yu, Yongying Jiang, Stephan Krapp, Alfred Lammens, Graham Trevitt, Martin R. Tremblay, Keith Mikule, Keith Wilcoxen, Jason B. Cross, Philip Jones, Joseph R. Marszalek, Richard T. Lewis
Indoleamine 2,3-dioxygenase 1 (IDO1), a heme-containing enzyme that mediates the rate-limiting step in the metabolism of l-tryptophan to kynurenine, has been widely explored as a potential immunotherapeutic target in oncology. We developed a class of inhibitors with a conformationally constrained bicyclo[3.1.0]­hexane core. These potently inhibited IDO1 in a cellular context by binding to the apoenzyme, as elucidated by biochemical characterization and X-ray crystallography. A SKOV3 tumor model was instrumental in differentiating compounds, leading to the identification of IACS-9779 (62) and IACS-70465 (71). IACS-70465 has excellent cellular potency, a robust pharmacodynamic response, and in a human whole blood assay was more potent than linrodostat (BMS-986205). IACS-9779 with a predicted human efficacious once daily dose below 1 mg/kg to sustain >90% inhibition of IDO1 displayed an acceptable safety margin in rodent toxicology and dog cardiovascular studies to support advancement into preclinical safety evaluation for human development.

History